Get the Stockscreener App
1.92
1.05%
0.02
After Hours:
1.93
0.01
+0.52%
Stereotaxis Inc stock is traded at $1.92, with a volume of 240.95K.
It is up +1.05% in the last 24 hours and up +2.67% over the past month.
Stereotaxis, Inc. designs, manufactures, and markets robotic systems and instruments for the treatment of abnormal heart rhythms in the United States and internationally. Its products include Niobe ES robotic magnetic navigation system that enables physicians to complete interventional procedures by providing image guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites; and Vdrive system, which offers navigation and stability for the diagnostic and therapeutic devices designed to enhance interventional procedures. The company also offers Odyssey solution, a real-time information solution to manage, control, record, and share procedures across networks. In addition, it provides disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company's disposables and other accessories include V-CAS and V-CAS Deflect catheter advancement systems; and V-loop circular and V-Sono ICE catheter manipulators. The company markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to design and develop a next-generation magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was founded in 1990 and is headquartered in St. Louis, Missouri.
See More
Previous Close:
$1.90
Open:
$1.92
24h Volume:
240.95K
Relative Volume:
0.54
Market Cap:
$187.16M
Revenue:
$32.38M
Net Income/Loss:
$-21.64M
P/E Ratio:
-7.6281
EPS:
-0.2517
Net Cash Flow:
$-13.78M
1W Performance:
+3.23%
1M Performance:
+2.67%
6M Performance:
-31.67%
1Y Performance:
-3.52%
1-Day Range:
$1.90
$1.97
1-Week Range:
$1.76
$1.9788
52-Week Range:
$1.74
$3.59
Stereotaxis Inc Stock (STXS) Company Profile
Name
Stereotaxis Inc
Sector
Industry
Phone
314-678-6100
Address
4320 Forest Park Avenue, Suite 100, St. Louis, MO
Compare STXS vs ISRG, BDX, MDLN, ALC, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STXS
Stereotaxis Inc
|
1.92 | 185.21M | 32.38M | -21.64M | -13.78M | -0.2517 |
ISRG
Intuitive Surgical Inc
|
451.38 | 160.21B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
144.17 | 41.62B | 21.92B | 1.76B | 2.63B | 6.1223 |
MDLN
Medline Inc
|
45.32 | 37.37B | 28.43B | 1.16B | 1.26B | 1.4457 |
ALC
Alcon Inc
|
74.45 | 35.82B | 10.40B | 980.00M | 1.61B | 1.9749 |
RMD
Resmed Inc
|
207.88 | 30.38B | 5.40B | 1.49B | 1.78B | 10.12 |
Stereotaxis Inc Stock (STXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jan-10-24 | Initiated | ROTH MKM | Buy |
| Jul-12-22 | Initiated | Aegis Capital | Buy |
| Jun-23-22 | Initiated | B. Riley Securities | Buy |
| Jan-05-22 | Initiated | Craig Hallum | Buy |
| Jan-05-22 | Initiated | Loop Capital | Buy |
| May-26-21 | Initiated | Piper Sandler | Overweight |
| Sep-08-20 | Initiated | Northland Capital | Outperform |
| Apr-09-20 | Initiated | Cowen | Outperform |
| Apr-07-20 | Initiated | Lake Street | Buy |
View All
Stereotaxis Inc Stock (STXS) Latest News
Stereotaxis to acquire Robocath for $20M upfront - MSN
Why Stereotaxis (STXS) Could Be One of the Best Robotics Stocks to Buy Under $30 - Insider Monkey
5 Best Robotics Stocks to Buy Under $30 - Insider Monkey
Stereotaxis stock up on first US MAGIC procedures post approval - MSN
Citizens Initiates Coverage of Stereotaxis (STXS) with Market Outperform Recommendation - MSN
STXS to acquire Robocath to lead in endovascular robotics market - MSN
Stereotaxis Inc. (STXS) reports Q4 loss, lags revenue estimates - MSN
Stereotaxis, Inc. spotlights RoboticEP system during interactive sessions at HRS2026 - Traders Union
Stereotaxis wins FDA clearance for Synchrony system, launches platform - MSN
Stereotaxis Stock Up on First U.S. MAGiC Procedures Post Approval - TradingView
Stereotaxis’ Catheter Earns Early Clinical Success Following FDA Approval - Diagnostic and Interventional Cardiology
Stereotaxis Has 1st U.S. Procedures with MAGiC Cardiac Ablation Catheter - Medical Product Outsourcing
Stereotaxis, Inc. enables first U.S. robotic arm procedures for complex CHD cases - Traders Union
Stereotaxis Announces First MAGiC Procedures in the United States - ChartMill
After the close, Stereotaxis will break down Q1 results on May 12 - Stock Titan
Stereotaxis to Report First Quarter 2026 Financial Results on May 12, 2026 - GlobeNewswire
Stereotaxis to acquire Robocath in deal aimed at expanding surgical robotics platform - Indian Pharma Post
Net current asset value per share of Stereotaxis, Inc. – LSX:A1J09L - TradingView
Stereotaxis to Acquire Robocath in Strategic 45 Million Dollar Deal - HarianBasis.co
Stereotaxis, Inc. sets sights on HRS2026 with live robotics demonstration - Traders Union
STXS to Acquire Robocath to Lead in Endovascular Robotics Market - TradingView
Stereotaxis to acquire Robocath for up to $45m - Yahoo Finance
Stereotaxis (STXS) to Acquire Robocath in Multi-Million Dollar D - GuruFocus
Stereotaxis Eyes Billions In Market Opportunity With Robocath Takeover - Benzinga
Stereotaxis to buy Robocath for up to $45M - MedTech Dive
Stereotaxis to Buy Robocath for up to $45M - Medical Product Outsourcing
St. Louis robotic surgery firm acquires French competitor - The Business Journals
Stereotaxis to acquire Robocath for up to $45M - MassDevice
Stereotaxis to Acquire Robocath in Strategic Robotics Deal - TipRanks
Stereotaxis to Acquire Robocath in Deal Worth Up to $45 Million - marketscreener.com
Stereotaxis to Acquire Robocath With $20M Upfront, Up to $25M Earnouts; Provides Interim Financing - TradingView
Stereotaxis to acquire Robocath for up to $45 million By Investing.com - Investing.com Canada
Stereotaxis (STXS) plans Robocath acquisition with $20M upfront and $25M earnout - Stock Titan
Stereotaxis Announces Definitive Agreement to Acquire Robocath - ChartMill
Stereotaxis, Inc. agreed to acquire an unknown majority stake in Robocath SAS for $45 million. - marketscreener.com
Stereotaxis, Inc. urges final day visits at EHRA2026 for hands on robotic EP demonstrations - Traders Union
Stereotaxis (STXS) CFO awarded 40,000 options at $1.87 strike price - Stock Titan
Aug Drivers: Is Stereotaxis Inc being accumulated by smart money2026 Levels & Daily Chart Pattern Signal Reports - baoquankhu1.vn
Inflation Data: Can Stereotaxis Inc keep up with sector leaders2026 Trading Volume Trends & Community Driven Trade Alerts - baoquankhu1.vn
Stereotaxis, Inc. (AMEX:STXS) Q1 2025 Earnings Call Transcript - MSN
Stereotaxis, Inc. promotes GenesisX at EHRA2026 kickoff in Paris - Traders Union
Bank Watch: Does Stereotaxis Inc align with a passive investing strategy2026 Year in Review & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Stereotaxis bags FDA clearance for next-gen cath lab tech - Indian Pharma Post
St. Louis-based Stereotaxis gets FDA clearance for new cath lab software platform - The Business Journals
Stereotaxis, Inc. (STXS) stock price, news, quote and history - Yahoo Finance Australia
STXS Rises After FDA Approval for Synchrony System, Broadens Digital Surgery Portfolio - Bitget
STXS Gains on FDA Nod for Synchrony System, Expands Digital Surgery - TradingView
Stereotaxis Inc Stock (STXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
0.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):